Optimization of codon composition and regulatory elements for expression of human insulin like growth factor-1 in transgenic chloroplasts and evaluation of structural identity and function
© Daniell et al; licensee BioMed Central Ltd. 2009
Received: 26 June 2008
Accepted: 03 April 2009
Published: 03 April 2009
Transgenic chloroplasts are potential bioreactors for recombinant protein production, especially for achievement of high levels of protein expression and proper folding. Production of therapeutic proteins in leaves provides transgene containment by elimination of reproductive structures. Therefore, in this study, human Insulin like Growth Factor-1 is expressed in transgenic chloroplasts for evaluation of structural identity and function.
Expression of the synthetic Insulin like Growth Factor 1 gene (IGF-1s, 60% AT) was observed in transformed E. coli. However, no native IGF-1 gene (IGF-1n, 41% AT) product was detected in the western blots in E. coli. Site-specific integration of the transgenes into the tobacco chloroplast genome was confirmed after transformation using PCR. Southern blot analysis confirmed that the transgenic lines were homoplasmic. The transgenic plant lines had IGF-1s expression levels of 11.3% of total soluble protein (TSP). The IGF-1n plants contained 9.5% TSP as IGF-1n, suggesting that the chloroplast translation machinery is more flexible than E. coli in codon preference and usage. The expression of IGF-1 was increased up to 32% TSP under continuous illumination by the chloroplast light regulatory elements. IgG-Sepharose affinity column chromatographic separation of Z domain containing chloroplast derived IGF-1 protein, single and two dimensional electrophoresis methods and mass spectrometer analysis confirmed the identity of human IGF-1 in transgenic chloroplasts. Two spots analyzed from 2-D focusing/phoresis acrylamide gel showed the correct amino acid sequence of human IGF-1 and the S. aureus Z-tag. Cell proliferation assays in human HU-3 cells demonstrated the biological activity of chloroplast derived IGF-1 even in the presence of the S. aureus Z tag.
This study demonstrates that the human Insulin like Growth Factor-1 expressed in transgenic chloroplasts is identical to the native protein and is fully functional. The ability to use plant chloroplasts as bioreactors to generate proteins of great economic value that retain their biological activity is an exciting and achievable goal that appears to be within our grasp.
Insulin-like growth factor 1 is an anabolic hormone produced in the liver that is known to stimulate proliferation and differentiation of many cell types and plays an important role in tissue renewal and repair . Growth hormone binds to specific receptors on the hepatocyte cell membrane and triggers a mechanism (largely undefined), that synthesizes and releases IGF-1 into the blood . The normal levels of IGF-1 are between 120–400 ng/ml . Because of important IGF-1 functions in the body, people who suffer IGF-1 deficiency also experience many harmful side effects . Patients with liver cirrhosis have a reduction of the GH receptor in the hepatocytes and the diminished synthesis of the liver parenchyma causes a significant decrease of IGF-I levels in the blood (20 ng/ml and frequently to undetectable levels). This reduction in IGF-1 results in systemic problems including muscle atrophy, osteopenia, hypogonadism, protein-calorie malnutrition, weight loss, and many others . Studies in rats with liver cirrhosis showed that treatments with low doses of IGF-I help to induce significant improvements in intestinal absorption , hypogonadism , and liver functions . Replacement therapy with IGF-1 in liver cirrhosis patients requires daily doses of 1.5 to 2 mg. Thus, a single patient would need to consume about 600 mg IGF-1per year. However, IGF-1 treatment is very expensive. In addition to the applications described above, IGF-1 is used in treatment of dwarfism , diabetes  and osteoporosis .
Currently, most of the IGF-1 that is available is synthesized in E. coli  or yeast . Construction and maintenance of fermentation systems are very expensive. In addition, formation of inclusion bodies in E. coli or variable biological activities of different forms of IGF-1 in yeast are disadvantages of current production systems. Transgenic plants are good expression systems for large-scale production of recombinant proteins at industrial levels. Plant systems have many advantages including the low cost of growing plants on a large scale, the availability of natural protein storage organs, and the established practices for their efficient harvesting, transporting, storing, and processing . It has been estimated that the cost of producing recombinant proteins in plants could be 10 to 50 fold lower than producing the same protein by E. coli via fermentation .
However one major drawback of expression of human blood proteins via the nuclear genome is their low levels of expression, mostly less than 1% of the total soluble protein. Some examples of these proteins are human serum albumin 0.02%, haemoglobin 0.05%, and erythropoietin 0.0026% of total soluble protein [16, 17]. Also, a synthetic gene coding for the human epidermal growth factor was expressed only up to 0.001% of total soluble protein in transgenic tobacco . IGF-1 expression level in transgenic rice and tobacco was in the range of 22–113 ng/mg protein or 0.002 – 0.011% total soluble proteín, after optimization of codons for plant expression and use of optimal regulatory sequences with or without leader peptides . Although improvements have been made recently for enhancing expression of foreign genes , most progress has been made in expression of vaccine antigens [20, 21] and monoclonal antibodies  using plant viral technology. However, there are not many examples of high level expression of human blood proteins using nuclear transgenic plants. The most commonly encountered challenges are random integration of transgenes into the nuclear genome leading to position effect and transgene silencing, resulting in low levels of foreign gene expression. The position effect could be eliminated by site specific integration of transgenes into the chloroplast genome [23, 24]. No gene silencing has been ever reported in transgenic chloroplasts. In spite of expression of transgenes up to 46% of the leaf protein  or 150–170 fold higher transcription than the nuclear transgene [26, 27], no gene silencing has been observed in transgenic chloroplasts. Yet another major advantage of transgene expression via the chloroplast genome is their containment because of maternal inheritance of chloroplast genome [28, 29]. Containment of foreign genes via pollen or seeds is achieved by their expression only in leaves or vegetative tissues and their harvest before emergence of reproductive structures.
Based on these advantages, several vaccine antigens and biopharmaceuticals have been expressed in chloroplasts and their efficacy has been evaluated. For example vaccine antigens have been expressed against bacterial, viral and protozoan pathogens and have been shown to be immunogenic and offer protection against pathogen challenge [30–36]. Similarly, several human blood proteins including somatotropin , interferon alpha , interferon gamma  and insulin , were expressed in chloroplasts and shown to be properly folded and fully functional. However, no detailed study has yet been reported on evaluation of the structure of human blood proteins or their amino acid sequence or codon usage. Therefore in this article, we investigate optimization of codon composition of the human IGF-1 and compare expression of the native and synthetic genes at different stages of growth and development of transgenic lines under normal or continuous illumination. After purification of chloroplast derived IGF-1 using IgG sepharose affinity column chromatography, 2-D, electrophoresis and mass spectrometer analyses were used to investigate structural identity. Cell proliferation assay was used to evaluate biological activity of chloroplast derived IGF-1.
Chloroplast vectors with native and synthetic IGF-1 genes
The IGF-1 gene was fused to the ZZ tag to facilitate the purification process. Creating this fusion increases the protein's stability and protects the polypeptide from proteolytic degradation. The pLDG-IGF-1n and pLDG-IGF-1s vectors were designed with the Glu-Asn-Leu-Tyr-Phe-Gln-Gly amino acid sequence, which is recognized by the Tobacco Etch Virus (TEV) protease and cuts between the Gln-Gly. In this way, the IGF-1 polypeptide can be released without any extra amino acids.
IGF-1 expression in E. coliusing chloroplast vectors
Confirmation of site-specific transgene integration
Evaluation of homoplasmy
Evaluation of chloroplast transcripts
IGF-1 Expression in Transgenic Chloroplasts
The transgenic tobacco lines were exposed to continuous light for 13 days to evaluate IGF-1 expression levels, because the psbA promoter and 5' UTR are regulated by light. ELISAs showed more than 2 fold increase in the expression levels after the transgenic lines were exposed for 5 days of continuous light (Figure 7B). The IGF-1s transgenic line (T0) had an IGF-1 expression level of 32.7% TSP and T1 transgenic line had 26.6% TSP, because these were younger plants. The IGF-1n-plant (T0) had an expression level of 32.4% TSP. The expression levels were measured again after 9 and 13 days. For both IGF-1s and IGF-1n, the ELISAs showed a decrease in the expression levels (Figure 7B), although the decrease was more significant in IGF-1n transgenic lines. Additionally, IGF-1 protein accumulation was measured in young, mature, and senescing leaves. A young leaf was taken from the top five leaves, the mature leaf was green and fully-grown from the mid-section of the plant, and the old leaf was senescent and from the very bottom of the plant. Figure 7C shows that all transgenic lines had a higher IGF-1 expression in mature leaves. Younger leaf cells contained fewer chloroplasts and the psbA was developmentally regulated; therefore, expression levels were less than mature leaves. Older senescent leaves had lower accumulation of IGF-1 probably due to higher proteolytic activity. Another experiment was performed to quantify IGF-1 expression during plant development by comparing seedlings and plants after 5 days and 15 days of growth in pots. The transgenic tobacco line showed an IGF-1 expression level of 2.71% TSP in the seedling, 3.2% TSP after 5 days in the pot and 4.9% TSP after 15 days in the pot (see Figure 7D), confirming developmental regulation of the psbA promoter. ELISA experiments showed that the expression levels between the T0 and the T1 transgenic lines were very similar (Figure 7E). Quantitation of IGF-1 in different fraction showed that it was present in both the total and soluble fractions (Figure 7F), suggesting that some of the IGF-1 is in the insoluble fraction.
Purification and characterization of IGF-1 expressed in chloroplasts
Chloroplast-derived IGF-1, at higher concentrations (dilutions between 8 –128) did not significantly stimulate the proliferation of the HU-3 cells; this could be due to some impurity present in these preparations that were obtained with rapid purification. However, >97% pure commercial IGF-1 also did not show dose dependent increase between 300 ng/ml and 10,000 ng/ml concentrations. These results suggest that both the commercial and plant synthesized IGF-1 have similar levels of mitogenic activity and that the apparent dip in the dose response curve at higher IGF-1concentrations may be due to currently unknown environmental factors that had an approximately equal effect on the two sources of IGF-1. Therefore, addition of chloroplast-derived IGF-1 resulted in a dose-dependent growth response of HU-3 cells, very similar to commercial IGF-1. Alterations in the mitogenic response to decreasing IGF-1 dosage are similar in both chloroplast-derived IGF and commercial IGF inoculated cell cultures. These observations argue against specific differences between chloroplast-derived and commercial IGF-1. Chloroplast-derived IGF-1 functioned efficiently in spite of the presence of ZZ-tag and possibly other impurities present after rapid purification.
Transplastomic lines express significant amounts of human IGF-1. The difference in IGF-1 expression levels is insignificant between the synthetic and native genes in the chloroplasts. This may be due to optimal levels of expression already achieved with the native gene and limitations of the chloroplast protein synthetic machinery other than codon usage. On the contrary, the IGF-1 polypeptide was only expressed in the E.coli cells that contain the IGF-1s. These results show that E. coli translational machinery may be different from chloroplast in codon preference and usage. Although previous studies used chloroplast vectors for expression of foreign proteins in E. coli, this is the first time a dramatic difference has been observed between these two systems in their translation machinery.
The psbA promoter and 5'UTR were used in the pLDG-IGF-1n and pLDG-IGF-1s vectors to enhance the protein expression. The expression levels increased more than 2 fold after five days in continuous light. Also, IGF-1 expression levels increased during plant development. Both light regulation and developmental regulation of the psbA gene is well known in the literature although this study has further confirmed the role of such regulatory elements using a human blood protein. This information will be useful in various biotechnology applications. Similarly, IGF-1 expression was measured in young, mature and old leaves. The IGF-1 expression was higher in mature leaves and this again provides an ideal time to harvest this protein in the green house or field.
Maternal inheritance of genetically modified chloroplast genomes and the absence of any reproductive structures when foreign proteins are expressed in leaves, offer efficient transgene containment and facilitates their safe production in the field [28, 29]. Two recent studies point out efficient control of maternal inheritance of transgenes in transplastomic tobacco. Ruf et al  set up a stringent selection system for paternal transmission by using male sterile maternal parents and transplastomic pollen donors conferring plastid specific antibiotic resistance and green fluorescence for visual screening. This selection system identified six among 2.1 million seedlings screened (frequency of 2.86 × 10-6) that showed paternal transmission of transgenes and the authors concluded that plastid transformation provides an effective tool to increase biosafety of GM crops. Svab and Maliga  examined the contribution of alien cytoplasm to rare paternal plastid transmission and reached similar conclusions. Transplastomic plants producing human therapeutic proteins have been already tested in the field after obtaining USDA-APHIS approval . Because of such unique advantages, transgenic chloroplasts have been used for expression of human therapeutic proteins [30–40, 44].
IgG-Sepharose affinity column chromatographic separation of Z domain containing chloroplast derived IGF-1 protein confirmed a protein with a molecular mass corresponding to human IGF-1. Staphylococcal protein A (SPA) is an immunoglobulin-binding receptor present on the surface of the gram positive bacterium Staphylococcus aureus. The strong and specific interaction between SPA and the constant part (Fc) of certain immunoglobulins (Ig) have made it useful for purification and detection of immunoglobulins in a variety of different applications [45, 46] and therefore in our study the ZZ tag was used for purification of IGF-1 fusion proteíns expressed in chloroplasts. SPA does not contain any cysteine residues that could interfere with the disulfide formation within a fused target protein . The hydroxylamine cleavage resulted in approximately 40% cleavage of the ZZ tagged IGF-1 to IGF-1 + ZZtag-IGF-1 as observed by acrylamide gel staining following gel electrophoresis. Hydroxylamine cleavage was more efficient than TEV protease and less expensive but resulted in full length IGF-1 with no extra amino acids. There is evidence that dependent upon the fusion protein, the ZZ tag can be more or less resistant to hydroxylamine cleavage. This may be responsible for the reduced level of ZZ-tag cleavage .
The presence of human IGF-1 in purified plant extracts was confirmed by single and two dimensional electrophoresis methods and the structural elements of chloroplast-derived IGF-1 was further confirmed by mass spectrometer analysis. Cell proliferation assays confirmed the biological activity of chloroplast derived IGF-1 and found that human HU-3 cells react strongly to the addition of chloroplast generated IGF-1 even in the presence of the S. aureus Z tag. Proper functionality of IGF-1 suggests that required disulfide bonds are formed. Presence of disulfide bonds in several chloroplast-derived human blood proteins including interferon alpha, gamma and somatotropin [37–39] was evaluated by their functionality in cell culture assays. Therefore, therapeutic proteins expressed in transgenic chloroplasts have proper post-translational modifications and are fully functional. While purification of chloroplast generated human IGF-1 to homogeneity remains to be attained, retention of significant biological activity of the ZZ tagged IGF-1 molecule indicates its effective biological usefulness even in an altered state. Therefore, the ability to use plant chloroplasts as bioreactors to generate proteins of great economic value that retain their essential biological activity is an exciting goal that appears to be within our grasp.
Recursive PCR and Primer Design
For synthesis of optimized IGF-1 (IGF-1s) gene, four primers were designed: two external primers of 56 bp and two internal primers of 100 bp. All the primers have an overlapping region of 20 bp. The 5' external primer was engineered to include the sequence of the TEV enzymatic cleave site and the 3' primer contained the NotI restriction site. In recursive PCR reaction, the external oligonucleotides were in higher concentration than the internal (20–30 pmol of the external primers and 0.2–0.3 pmol of the internal primers). The lower concentration of the internals oligonucleotides assisted in avoiding unwanted products.
Two different parts were used in the recursive PCR [49, 50]. In the first part, the reaction were run through 10 cycles using the following temperature sequence: 94°C for 30 seconds to denature the DNA, 55°C for 30 seconds for annealing primes, and 72°C for 1 minute to synthesize DNA. An incubation period of 7 minutes at 72°C followed after the cycles ended. The primers were designed to have an annealing temperature of 55°C to avoid unspecific binding of the primers. The second part consisted of 30 cycles, denaturing the DNA for 30 seconds at 94°C, then primers annealing for 30 seconds at 65°C, followed by DNA synthesis for 7 minutes at 72°C. The PCR product was run on 1.5% agarose gel at 65 volts for 55 minutes to visualize amplified products. The IGF-1s was cloned into the pBluescript KS II, and E. coli cells were transformed with this vector.
Bombardment and Selection of Transgenic Lines
Sterile leaves were bombarded using the Bio-Rad PDS-1000/He biolistic device [51, 52]. The bombarded leaves were incubated in the dark for 48 hours and then cut and placed in RMOP medium with 500 μg/ml of spectinomycin.
The plant DNA was extracted from leaves using the Qiagen Dneasy Plant Mini Kit (Quiagen). The 3P and 3M primers were used to perform PCR on transformed and untransformed plants [51–53]. Samples were run for 30 cycle with the following sequence: 94°C for 1 min., 65°C for 1.5 min., and 72°C for 2 min. PCR products were analyzed on 0.8% agarose gel.
Southern Blot Analysis
The plant DNA of the transgenic and wild type tobacco plants were digested with BglII, and separated on 0.8% agarose gel and transferred to a nylon membrane. The 0.8 kb probe was generated by digesting pLD-CtV2 (that contains the trnI and trnA genes) vector with BamHI and BglII and was labeled with 32P (Amersham). The probe was hybridized with the membrane using the QUICK-HYB hybridization solution and protocol (Stratagene).
ELISA was used to quantify the IGF-1 expression levels in different transgenic lines. Different concentrations of 100 mg leaves (transformed and untransformed plants) were ground with liquid nitrogen. Bicarbonate buffer, 500 μl, pH 9.6 (15 mM Na2CO3, 35 mM NaHCO3, and 0.1% Tween 20, pH 9.6) was used to resuspend the ground mixture and incubated overnight at 4°C. Diluted sample (1:3000) was added in each well (100 μl) of the plate and this was done in duplicate. Bicarbonate buffer was used as blank. The plate was incubated overnight at 4°C. After washing the wells thrice with washing buffer, PBST (PBS and 0.05% Tween 20), mouse anti human IGF-1 diluted 1 μg/ml in 0.01 M PBST containing 0.3% milk (100 μl/well) was added and incubated for 2 h at 37°C. The wells were washed and incubated with 1:10,000 goat anti mouse IgG-alkaline phosphatase conjugate in 0.01 M PBST containing 0.3% milk (100 μl/well) for 2 h at 37°C. The plate was developed with TMB substrate (100 μl/well, American Qualex) for 30 minutes at room temperature and the reaction was stopped by addition of 50 μl/well of 2 M sulfuric acid and the plates were read at 405 nm. For a standard curve, purified commercially available human IGF-1 (R&D Systems) was diluted with bicarbonate buffer to concentrations between 3 and 25 ng/ml and processed as above. Total soluble plant protein concentration was determined using the DC Protein Microassay (Bio-Rad). IGF-1 expression levels were calculated as a percentage of the total soluble protein.
One hundred mg of tobacco leaves were ground in liquid nitrogen and resuspended in 200 μl of extraction buffer (200 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM EDTA, 4 mM PMSF) . Leaf extracts were boiled for 5 minutes in the sample buffer (0.5 M Tris-HCl, pH 6.8, 2.5 ml glycerol, 10% SDS, 0.5% bromophenol blue reached a total volume 9.5 ml with water) (Bio-Rad). All samples were electrophoresed in 15% resolving and 4% stacking gels using the buffer system of Laemmli. The membrane was blocked for 20 minutes at room temperature with PBS and 3% non-fat milk (PBS-milk). Then, the blot was incubated with anti-IGF-1 (Upstate Biotechnology, diluted in PBS-milk until it achieved a final concentration 1 μg per ml) overnight at 4°C. The membrane was washed twice with water. The secondary antibody used was a Goat Anti Mouse IgG conjugated to Horseradish Peroxidase (American Qualex Antibodies) at a 1:5000 dilution, and was added to membranes in blocking solution and incubated for one hour. The blot was washed with water. A final wash was done for 5 minutes in PBS with 0.05% Tween 20. Development was performed by the chemiluminescent method (Pierce).
Following elution from the immuno-affinity column, the protein samples were concentrated by speed vac evaporation and diluted 1:2 in 1× Gel-loading buffer (50 mM Tris, 2% SDS, 0.05% Brome-Phenol Blue, 10 v/v% glycerol and 2 μl DTT (dithiothreitol). The samples were heated at 95°C for 5 min, and 20 μl (protein conc. 500 μg/ml) of the sample was loaded onto the gel. Electrophoresis was performed at 160 V-, in 1× Laemmli running buffer (5× Laemmli: 500 ml-in water solution 7.5 g Tris, 47 g glycine, 2.5 g SDS). Capillary blotting of proteins was carried out overnight in transfer buffer (3 g Tris, 14.4 g glycine, 200 ml methanol per liter). The nitrocellulose membrane was washed for 5–10 min with TST-buffer (4.5 g NaCl, 250 μl Tween 20, 25 ml in 500 ml 1 M Tris, pH 7.5), then blocked in TST containing 5% dry milk (TST = 5 g dry milk in 100 ml) for 30 min in glass tubes of the DNA hybridization equipment, with slow rotation. The primary antibody (goat a-human IGF-I, SIGMA Cat#8773) was diluted1:1250 in TST (with 2.5% dry milk); membranes were rinsed in distilled water. The primary antibody (10 ml) was added to membranes, and incubated for 2 h at room temp with gentle shaking. Membranes were washed 5 times in distilled water followed by 3 × 5 times in TST, (50 ml). The secondary antibody (Rabbit a-goat alkaline phosphatase-conjugate, Sigma Cat#4049), or monoclonal a-goat alkaline phosphatase-conjugate- Sigma Cat#8062) was diluted in TST buffer (1:10000, 20000, 50000), added to blots and incubated with gentle rotation on an orbital shaker for 1 h. Blots were washed 3 × 5 times in TST, followed by 5 times in distilled water. Immunoblots were developed for 20–40 min in NBT substrate: made up of 5 mg NBT (nitrotetrazolium blue, Sigma) diluted in100 μl of 70% DMF (dimethyl-formamide) solution; 82 μl BCIP (5-bromo-4-chloro-3-indolyl phosphate disodium salt) was added to 10 ml substrate buffer (100 ml: 10 ml 1 M Tris, 2 ml 5 M NaCl and 5 ml 1 M MgCl2). Blots were stained at 4°C overnight. The reaction was stopped by dilution of the substrate in cold tap water.
Purification of IGF-1 from transplastomic leaves
Transformed tobacco leaves (50 g) were ground to a fine powder in a liquid nitrogen in pre-cooled mortar. The plant powder was thawed by addition of two volumes (100 ml) of cold Extraction Buffer A (50 mM Tris HCl, pH 8.0, containing 200 mM NaCl, 100 mM EDTA and 1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.1% Nonidet P-40). The homogenate was centrifuged in 50 ml Oakridge tubes at 9,000 rpm, 10 min, at 4°C in a pre-cooled SA-600 rotor, in a Sorvall RC-5B centrifuge to remove cell debris. The non-IGF-1 plant proteins in the supernatant were precipitated by the addition of solid ammonium sulfate to 30% saturation (w/v), while the IGF-1 remained in the soluble fraction. The mixture was centrifuged at 9,500 rpm in a Sorvall SA-600 rotor at 4°C for 30 min. The supernatant containing the IGF-1 was raised to 65% saturation with ammonium sulfate and the mixture was centrifuged as before. The IGF-1 was now precipitated in the pellet. The pellet was resuspended in a small volume (3–4 ml) of Extraction Buffer B (25 mM Tris-HCl, pH 7.5, 0.01% thiodiglycol and 10 μM PMSF) – 10×. The mixture was dialysed against 1.0 liter of extraction buffer B at 4°C for 6 hrs in dialysis tubing with a molecular weight cutoff of 7,000 kDa or less. The dialysate was centrifuged as before at 9,500 rpm in the SA-600 rotor for 15 min to sediment insoluble proteins. The supernatant containing the IGF-1 was adjusted to 0.15 M NaCl and loaded onto a IgG-Fast Flow 6 Sepharose (Sigma) immunoadsorbent column (10 ml bed vol), equilibrated with TST buffer (50 mM Tris-HCl, pH 7.6, 120 mM NaCl, 0.05% Tween 20). Proteins other than ZZ-IGF were eluted from the column by washing with 10–20 column volumes of TST buffer. The Tween 20 detergent was removed from the column by washing with 2 volumes of 5 mM ammonium acetate, pH 4.8. The ZZ-IGF-1 fusion protein was eluted from the column with 0.4 M acetic acid, pH 3.4 at a low linear flow rate (20 cm/hr) to obtain a sharp IGF-1 peak. The column eluate was collected (2.0 ml fractions), and monitored (OD280) for the appearance of ZZ-IGF-1 protein which eluted after the column volume. The fractions containing the ZZ-IGF-1 protein were pooled and the protein concentration was determined spectrophotometrically by comparison of the OD260/280 nm ratio, or more precisely by Bradford protein assay. Residual salt was removed by dialysis for 2–3 hrs against 1 l of 5 mM ammonium acetate, pH 6.0, at 4°C using dialysis tubing with a 3.5 kDa cutoff (Pierce). A sample of the ZZ-IGF-1 protein was subjected to electrophoresis on a 15% acrylamide gel to examine the molecular weight of the ZZ tagged IGF-1.
The ZZ-linker was cleaved from the IGF-1, by dissolving 2.0 mg of previously isolated tobacco ZZ-tagged IGF-1 fusion protein in 1.0 ml of ZZ Buffer without hydroxylamine (0.2 M Tris-HCl, pH 9.2, 1 mM EDTA). Cleavage of the ZZ moiety from the IGF-1 was carried out by addition of an equal volume of ZZ buffer (0.2 M Tris-HCl, pH 9.2, 2 M hydroxylamine, 1 mM EDTA).containing 2.0 M hydroxylamine. The mixture was incubated at 45°C for six hours and the reaction was terminated by lowering the pH to 6.0 with acetic acid. Cleaved IGF-1 was estimated by separation of the two forms by acrylamide gel electrophoresis. Hydroxylamine was removed from the mixture by first lowering the pH to 6.0 with glacial acetic acid (measured with pH paper), followed by dialysis of the mixture for 2 hrs at 4°C in 1.0 liter of 50 mM ammonium acetate buffer, pH 6.0. The ZZ-tagged-IGF-1/IGF-1 mixture was lyophilized yielding a tan powder. After resuspension of the powder in a small volume (0.5 ml) of distilled water, the mixture was separated by polyacrylamide gel electrophoresis on a 15% acrylamide gel in a BioRad minigel electrophoresis apparatus for 1 hr, at 100 Volts. The protein bands (2) representing IGF-1 and ZZ-tagged-IGF-1, were stained by immersion of the gel in "gelcode" (Pierce), bromophenol blue stain for 2 hr. The gel was destained in distilled water prior to photographic documentation.
To remove the contaminating ZZ ligand and uncleaved ZZ-IGF-1 from the IGF-1 molecules, the cleavage mixture was passed over a small (3.0 ml) IgG-sepharose column previously washed with 10× vol of TST, 2× vol of TS and 2× vol of 5 mM ammonium acetate, pH 4.5. IGF-1 molecules passed through the column following the void volume (1.0 ml, determined by the elution of blue dextran), while the free ZZ domains and uncleaved ZZ-IGF bound to the IgG -sepharose. After collection of the column eluate (1.0 ml fractions), the amount of IGF-1 protein was measured by Bradford protein assay and the protein diluted with sterile water, divided into aliquots and frozen at -20°C for use in biological assays or structural studies.
Cell Proliferation Assays
The biological activity of partially purified human IGF-1 preparations isolated from tobacco chloroplasts was established by measurement of IGF-1 effects on mammalian cell proliferation. Briefly, human megakaryoblastic (HU-3) cells carrying the IGF-1 receptor were cultured in RPMI-1640 medium + 10% calf serum. Cells in the logarithmic phase of growth were seeded into 96-well plates at a concentration of 25,000 cells/well in 50 μL RPMI-1640 containing 0.1 BSA and 0.5–1% calf serum. At the beginning of the assay, commercial human IGF-1 (Sigma), or IGF-1 partially purified from tobacco chloroplasts (50 μL) was added to each well at concentrations from 0.001 μg/ml to 10 μg/ml. The cell cultures were incubated at 37°C for 48 hours and a portion of each culture was stained with Trypan Blue dye to quantify cell viability prior to measurements of cell proliferation as determined most reliably by cell counting by hemocytometer.
Murine 3T3 fibroblasts also carrying the IGF-1 receptor were maintained in DMEM medium and seeded in 96-well plates from 2,000 cells/well to concentrations as high as 20,000 cells/well in 50 μL DMEM + 0.1% BSA containing 0.1–1% calf serum. IGF-1 (50 μL) was added in ascending concentrations from 0.001 to 10 μg/ml. Forty eight hours later (some time after 7 days) cell proliferation was measured by the CyQUANT NF Cell proliferation assay (Invitrogen Inc., San Diego, CA) and by hemocytometer counting. Proliferation was measured by fluorescence determination of DNA replication based on intercalation of a fluorescent dye into double stranded DNA. Cell proliferation was determined according to the instructions supplied by the manufacturer. Red, blue and green lines represent the best fit of the respective data points for each proliferation assay treatment. The commercial human IGF-1 used in the assay was Sigma-Aldrich Cat#3769 (10 μg-0.001 μg/ml).
The investigations reported in this article were supported in part by grants from USDA 58-3611-7-610 and NIH R01 GM 63879 to Henry Daniell. The native IGF-1 gene was kindly provided by Drs. Puri Fortes and Jesus Prieto, University of Navarra, Spain. Authors thank Dr. Anderson Kanagaraj for help with preparation of figures.
- Jones JH, Clemmons DR: Insulin like growth factors and their binding proteins: biological functions. Endocr Rev. 1995, 16: 3-10.
- Feld S, Hirschberg R: Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev. 1996, 17: 423-480.
- Walsh G: Biopharmaceuticals: biochemistry and biotechnology. 1998, John Wiley and Sons, England, 235-243. 1
- Kim S, Lee Y: High-level expression and simple purification of recombinant human insulin-like growth factor I. J Biotechnol. 1996, 48: 97-105.View Article
- Blomsma MC, de Knegt RJ, Dullaart RP, Jansen PL: Insulin-like growth factor- I in liver cirrhosis. J Hepatology. 1997, 27: 1133-38.View Article
- Castilla-Cortázar I, Picardi A, Tosar A, Ainzúa J, Urdaneta E, García M, Pascual M, Quiroga J, Prieto J: Effect of insulin-like growth factor I on in vivo intestinal absorption of D-galactose in cirrhotic rats. American J Physiol. 1999, 276: G37-G42.
- Castilla-Cortazar I, García M, Quiroga J, Diez N, Diez-Caballero F, Calvo A, Diaz M, Prieto J: Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis. Hepatology. 2000, 31: 592-600.View Article
- Castilla-Cortázar I, García M, Muguerza B, Quiroga J, Perez R, Santidrian S, Prieto J: Hepatoprotective effects of Insulin-like Growth Factor I in Rats with Carbon Tetrachloride-induced Cirrhosis. Gastroenterology. 1997, 113: 1682-1691.View Article
- Laron Z, Anin S, Klipper-Aurbach Y, Klinger B: Effects of insulin-like growth factor on linear growth, head circumference, and body hair in patients with Laron-type dwarfism. Lancet. 1992, 339: 1258-1261.View Article
- Bach M, Chin E, Bondy C: The effects of recombinant insulin-like growth factor I (IGF-I) on growth hormone, IGF-II, IGF binding protein and blood glucose levels in normal and diabetic adolescents. Ped Res. 1993, 33: 190-198.View Article
- Ebeling P, Jones J, O'Fallon W, Janes C, Riggs B: Short-term effects of recombinant human insulin growth factor I on bone turnover in normal women. J Clin Endocrinol Metab. 1993, 77: 1384-1387.
- Joly JC, Leung WS, Swartz JR: Overexpression of E. coli oxidoreductases increases recombinant insulin-like growth factor accumulation. Proc Natl Acad Sci USA. 1998, 95: 2773-2777.View Article
- Gill R, Verma C, Wallach B, Urso B, Pitts J, Wollmer A: Modeling of the disulphide-swapped isomer of human insulin-like growth factor-1: implications for receptor binding. Protein Eng. 1999, 2: 297-303.View Article
- Kusnadi A, Nikolov Z, Howard J: Production of recombinant proteins in transgenic plants: practical considerations. Biotechnology and Bioengineering. 1997, 56: 473-484.View Article
- Giddings G, Allison G, Brooks D, Carter A: Transgenic plant as factories for biopharmecuticals. Nat Biotechnology. 2000, 18: 1151-1155.View Article
- Dieryck W, Pagnier J, Poyart C, Marden M, Gruber V, Bournat P, Baudino S, Merot B: Human hemoglobin from transgenic tobacco. Nature. 1997, 386: 29-30.View Article
- May G, Mason H, Lyons P: Application of transgenic plants as production systems for pharmaceuticals. American Chemical Society symposium. 1996, 13: 196-204.
- Panahi M, Alli Z, Cheng X, Belbaraka L, Belgoudi J, Sardana R, Phipps J, Altosaar I: Recombinant protein expression plasmids optimized for industrial E. coli fermentation and plant systems produce biologically active human insulin-like growth factor-1 in transgenic rice and tobacco plants. Transgenic Research. 2004, 13: 245-259.View Article
- Streatfield SJ: Approaches to achieve high level heterologous protein production in plants. Plant Biotechnol J. 2007, 5 (1): 2-15.View Article
- Gleba Y, Klimyuk V, Marillonnet S: Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol. 2007, 18: 134-141.View Article
- Santi L, Giritch A, Roy CJ, Marillonnet S, Klimyuk V, Gleba Y, Webb R, Arntzen CJ: Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system. Proc Natl Acad Sci USA. 2006, 103: 861-866.View Article
- Hiatt A, Pauly M: Monoclonal antibodies from plants: a new speed record. Proc Natl Acad Sci USA. 2006, 103: 14645-14646.View Article
- Kamarajugadda S, Daniell H: Chloroplast derived ántrax and other vaccine antigens: their immunogenenic and immunoprotective properties. Expert Rev Vaccines. 2006, 5: 839-849.View Article
- Verma D, Daniell H: Chloroplast vector systems for biotechnology applications. Plant Physiol. 2007, 145: 1129-1145.View Article
- De Cosa B, Moar W, Lee S, Miller M, Daniell H: Overexpression of the Bt cry 2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat Biotechnology. 2000, 19: 71-74.
- Lee SB, Kwon HB, Kwon SJ, Park SC, Jeong MJ, Han SE, Byun MO, Daniell H: Accumulation of trehalose within transgenic chloroplasts confers drought tolerance. Molecular Breeding. 2003, 11: 1-13.View Article
- Dhingra A, Portis AR, Daniell H: Enhanced translation of achloroplast expressed RbcS gene restores SSU levels and photosynthesis in nuclear antisense RbcS plants. Proc Natl Acad Sci USA. 2004, 101: 6315-6320.View Article
- Daniell H: Molecular strategies for gene containment in transgenic crops. Nat Biotechnol. 2002, 20: 581-586.
- Daniell H: Transgene containment by maternal inheritance: effective or elusive?. Proc Natl Acad Sci USA. 2007, 104: 6879-6880.View Article
- Daniell H, Lee S, Panchal T, Wiebe P: Expressioin of cholera toxin B subunit gene and assembly as functional oligomers in transgenic chloroplasts. J Mol Biol. 2001, 5: 1001-1009.View Article
- Tregoning JS, Nixon P, Kuroda H, Svab Z, Clare S, Bowe F, Fairweather N, Ytterberg J, van Wijk KJ, Dougan G, Maliga P: Expression of tetanus toxin fragment C in tobacco chloroplasts. Nucleic Acids Res. 2003, 31: 1174-9.View Article
- Molina A, Hervás-Stubbs S, Daniell H, Mingo-Castel AM, Veramendi J: High-yield expression of a viral peptide animal vaccine in transgenic tobacco chloroplasts. Plant Biotechnol J. 2004, 2: 141-53.View Article
- Koya V, Moayeri M, Leppla SH, Daniell H: Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun. 73: 8266-8274.
- Glenz K, Bouchon B, Stehle T, Wallich R, Simon MM, Warzecha H: Production of a recombinant bacterial lipoprotein in higher plant chloroplasts. Nat Biotechnol. 2006, 24: 76-77.View Article
- Chebola S, Daniell H: Stable expression of Gal/GalNAc lectin of Entamoeba histolytica in transgenic chloroplasts and immunogenicity in mice towards vaccine development for amoebiasis. Plant Biotechnol J. 2007, 5: 230-239.View Article
- Arlen PA, Singleton M, Adamovicz JJ, Ding Y, Davoodi-Semiromi A, Daniell H: Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun. 2008, 76: 3640-3650.View Article
- Staub JM, Garcia B, Graves J, Hajdukiewicz PT, Hunter P, Nehra N, Paradkar V, Schlittler M, Carroll JA, Spatola L, Ward D, Ye G, Russell DA: High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol. 2000, 18: 333-338.View Article
- Arlen PA, Falconer R, Cherukumilli S, Cole A, Cole AM, Oishi KK, Daniell H: Field production and functional evaluation of chloroplast-derived interferon-alpha2b. Plant Biotechnol J. 2007, 5: 511-25.View Article
- Leelavathy and Reddy: Chloroplast expression of his-tagged gus-fusions: a general strategy to overproduce and purify foreign proteins using transplastomic plants as bioreactors. Molecular Breeding. 2003, 11: 49-58.View Article
- Ruhlman T, Ahangari R, Devine A, Samsam M, Daniell H: Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts–oral administration protects against development of insulitis in non-obese diabetic mice. Plant Biotechnol J. 2007, 5: 495-510.View Article
- Eibl C, Zou Z, Kim M, Mullet J, Koop H: In vivo analysis of plastid psbA, rbcL, and rpl32 UTR elements by chloroplast transformation: tobacco plastid gene expression is controlled by modulation of transcript levels and translation efficiency. Plant J. 19: 333-345.
- Ruf S, Karcher D, Bock R: Determining the transgene containment level provided by chloroplast transformation. Proc Natl Acad Sci USA. 2007, 104: 6998-7002.View Article
- Svab Z, Maliga P: Exceptional transmission of plastids and mitochondria from the transplastomic pollen parent and its impact on transgene containment. Proc Natl Acad Sci USA. 2007, 104: 7003-7008.View Article
- Bally S, Paget E, Droux M, Job C, Job D, Dubald M: Both the stroma and thylakoid lumen of tobacco chloroplasts are competent for the formation of disulfide Bonds in recombinant proteins. Plant Biotechnol J. 2008, 6: 46-61.
- Langone JJ: Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci. Advances in Immunology. Edited by: Dixon FJ, Kunhel HG. 1982, Academic Press, 32: 157-252.
- Stahl S, Nygren PA: The use of gene fusions to protein A and protein G in immunology and biotechnology. Pathol Biol. 1997, 45: 66-76.
- Löfdahl S, Guss B, Uhlen M, Philipson L, Lindberg : Gene for staphylococcal protein A. Proc Natl Acad Sci USA. 1983, 80: 697-701.View Article
- Stahl S, Nygren P, Uhlen M: Detection and isolation of recombinant proteins based on binding affinity of reporter: Protein A. Recombinant Protein Protocols: Detection and Isolation. Edited by: Tuan RS. 1997, Humana Press, 63: 103-118.View Article
- Prodromou C, Pearl L: Recursive PCR: a novel technique for total gene synthesis. Protein Engineering. 1992, 5: 827-829.View Article
- Casimiro DR, Wright PE, Dyson HJ: PCR-based gene synthesis and protein NMR spectroscopy. Structure. 1997, 5: 1407-1412.View Article
- Verma D, Samson NP, Koya V, Daniell H: A protocol for expression of foreign genes in chloroplasts. Nature Protocols. 2008, 3: 739-758.View Article
- Daniell H: Transformation and foreign gene expression in plants mediated by microprojectile bombarment. Methods Mol Biol. 1997, 62: 463-89.
- Guda C, Lee S, Daniell H: Stable expression of a biodegradable protein-based polymer in tobacco chloroplasts. Plant Cell Rep. 2000, 19: 257-62.View Article
- Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH: A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol. 1998, 16: 934-938.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.